COMPANY

Click Therapeutics, Inc.

HQ: New York, NY source · clicktherapeutics.com ↗ · Mid-Atlantic

FDA-cleared device company Clinical Phase 3

Also known as Click Therapeutics · 19 sources

Keywords: medical device Schizophrenia Migraine Episodic Migraine Headache Multiple Sclerosis Nicotine Addiction Drug Addiction Drug Dependence Substance Use Disorder Tobacco Dependence Negative Symptoms in Schizophrenia Psychological Stress Loneliness Covid19 Stress Psoriasis Atopic Dermatitis Lung Cancer Breast Cancer Mild Cognitive Impairment Rheumatoid Arthritis Diabetic Neuropathy Fibromyalgia Irritable Bowel Syndrome Smoking Cessation Smoking Behaviors Smoking Reduction Cigarette Smoking Smoking Nicotine Dependence major depressive disorder CT-155 Study App Clinical Learning Study smartphone app (i.e., the study app) ReMMi-D Digital Therapeutic CT-155 smartphone app CT-156-C-001 CT-100-004-A CT-100-004-B

Location: New York, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

$50.0MRaised (2 yrs)16Trials (company is sponsor)2NIH grants

Funding and NIH signals

SEC Form D raise Raised $50M (Form D filed Oct 1, 2026). SEC Form D 0001623326-26-000001 (Oct 1, 2026)
Evidence (1 event)
- Oct 1, 2026 · SEC Form D 0001623326-26-000001
  Name of Issuer: Click Therapeutics, Inc.; CIK: 1623326; Address: New York, NY; Submission type: D; Filing date: 2026-10-01; Industry Group: Other Health Care; Date of First Sale: 2026-04-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 49999999; Total Amount Sold: 49999999; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Apr 9, 2026 Raise Private equity round — Series D: $50M (total, as published), announced Apr 9, 2026. Source: company release on GlobeNewswire. source ↗
May 6, 2024 Trial start Not phased (device or behavioral study): An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia. source ↗
Dec 4, 2023 Trial start Not phased (device or behavioral study): An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis source ↗
Oct 19, 2023 Trial start Not phased (device or behavioral study): An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer source ↗
Sep 20, 2023 Trial start Not phased (device or behavioral study): A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia source ↗
Sep 12, 2023 Trial start Phase 3: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia source ↗
Jul 21, 2023 Trial start Phase 3: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C) source ↗
Mar 31, 2023 Trial start Phase 3: Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia source ↗
Mar 28, 2023 Trial start Not phased (device or behavioral study): Study of Two Digital Therapeutics for the Prevention of Episodic Migraine source ↗
Oct 10, 2022 Trial start Not phased (device or behavioral study): Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training source ↗
Jul 5, 2022 Trial start Not phased (device or behavioral study): 7-week Study With CT-155 in People With Schizophrenia source ↗
May 13, 2022 Trial start Not phased (device or behavioral study): Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms source ↗
Mar 31, 2022 Trial start Not phased (device or behavioral study): Exploratory Study of a Digital Therapeutics in People With Schizophrenia source ↗
Mar 12, 2021 Trial start —: Clinical Learning Study for a Mobile Smoking Cessation Program source ↗
Oct 29, 2020 Trial start Not phased (device or behavioral study): Ecological Momentary Assessment and Text Message Intervention for Stress Management source ↗
Oct 25, 2018 Trial start Not phased (device or behavioral study): Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification source ↗
2016-05 Trial start Not phased (device or behavioral study): Clinical Trial of Smoking Cessation Mobile Phone Program source ↗

Funding

Raised: $50.0M. Last 2 years.

Apr 9, 2026 Private equity round — Series D: $50M (total, as published), announced Apr 9, 2026. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 16

Record	Title	Phase	Status	Start	Primary completion
NCT05838625	Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia	Phase 3	Completed	Mar 31, 2023	Jun 20, 2025 (actual)
NCT06067984	An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia	Phase 3	Completed	Sep 12, 2023	Jun 13, 2025 (actual)
NCT05438160	Exploratory Study of a Digital Therapeutics in People With Schizophrenia	Not phased (device or behavioral study)	Completed	Mar 31, 2022	Jul 31, 2022 (actual)
NCT05853900	Study of Two Digital Therapeutics for the Prevention of Episodic Migraine	Not phased (device or behavioral study)	Completed	Mar 28, 2023	May 7, 2024 (actual)
NCT05486312	7-week Study With CT-155 in People With Schizophrenia	Not phased (device or behavioral study)	Completed	Jul 5, 2022	Sep 22, 2022 (actual)
NCT04907942	Ecological Momentary Assessment and Text Message Intervention for Stress Management	Not phased (device or behavioral study)	Completed	Oct 29, 2020	Dec 18, 2020 (actual)
NCT06136936	A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia	Not phased (device or behavioral study)	Completed	Sep 20, 2023	Jan 18, 2024 (actual)
NCT06275659	An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis	Not phased (device or behavioral study)	Completed	Dec 4, 2023	Feb 23, 2024 (actual)
NCT06486948	An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.	Not phased (device or behavioral study)	Completed	May 6, 2024	Aug 9, 2024 (actual)
NCT06004388	Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)	Phase 3	Completed	Jul 21, 2023	May 21, 2024 (actual)
NCT06136923	An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer	Not phased (device or behavioral study)	Completed	Oct 19, 2023	Apr 18, 2024 (actual)
NCT05438147	Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms	Not phased (device or behavioral study)	Completed	May 13, 2022	Sep 6, 2022 (actual)
NCT05573685	Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training	Not phased (device or behavioral study)	Completed	Oct 10, 2022	Feb 6, 2023 (actual)
NCT05440721	Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification	Not phased (device or behavioral study)	Withdrawn	Oct 25, 2018	2022-07 (estimated)
NCT04857515	Clinical Learning Study for a Mobile Smoking Cessation Program	Not listed	Completed	Mar 12, 2021	Jun 28, 2021 (actual)
NCT02656745	Clinical Trial of Smoking Cessation Mobile Phone Program	Not phased (device or behavioral study)	Completed	2016-05	2016-09 (actual)

NIH awards 2

Annual award amounts. Total $450K.

Apr 4, 2019 NIH award 1R43MH119918-01 FY2019: $224,932 awarded for that fiscal year; activity R43 (SBIR); PI IACOVIELLO, BRIAN; recipient as written: CLICK THERAPEUTICS, INC., NEW YORK, NY. Content Validation for a Digital Thera source ↗
May 4, 2018 NIH award 1R43DA045395-01A1 FY2018: $224,951 awarded for that fiscal year; activity R43 (SBIR); PI IACOVIELLO, BRIAN; recipient as written: CLICK THERAPEUTICS, INC., NEW YORK, NY. Clinical trial of an innovative digi source ↗